These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1690433)

  • 21. Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity.
    Roubini E; Laufer R; Gilon C; Selinger Z; Roques BP; Chorev M
    J Med Chem; 1991 Aug; 34(8):2430-8. PubMed ID: 1714957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor.
    Nikolaus S; Huston JP; Hasenöhrl RU
    Eur J Pharmacol; 1999 Apr; 370(2):93-9. PubMed ID: 10323256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of neuropeptides in learning: focus on the neurokinin substance P.
    Huston JP; Hasenöhrl RU
    Behav Brain Res; 1995 Jan; 66(1-2):117-27. PubMed ID: 7538769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive reinforcing effects of substance P in the rat globus pallidus revealed by conditioned place preference.
    Kertes E; László K; Berta B; Lénárd L
    Behav Brain Res; 2010 Dec; 215(1):152-5. PubMed ID: 20600338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of substance P on rat gastrointestinal transit.
    Silkoff P; Karmeli F; Goldin E; Ewenson A; Gilon C; Chorev M; Laufer R; Selinger Z; Rachmilewitz D
    Dig Dis Sci; 1988 Jan; 33(1):74-7. PubMed ID: 2448096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aversive effects of the C-fragment of Substance P in the dorsal periaqueductal gray matter.
    de Araújo JE; Huston JP; Brandão ML
    Exp Brain Res; 1998 Nov; 123(1-2):84-9. PubMed ID: 9835395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of a 'septide-sensitive' inflammatory response in rat skin.
    Ahluwalia A; Giuliani S; Maggi CA
    Br J Pharmacol; 1995 Oct; 116(4):2170-4. PubMed ID: 8564245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substance P and behavior: opposite effects of N-terminal and C-terminal fragments.
    Hall ME; Stewart JM
    Peptides; 1983; 4(5):763-8. PubMed ID: 6197702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-lasting mnemotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning.
    Tomaz C; Silva AC; Nogueira PJ
    Braz J Med Biol Res; 1997 Feb; 30(2):231-3. PubMed ID: 9239309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The substance P fragment SP(1-7) stimulates motor behavior and nigral dopamine release.
    Hall ME; Stewart JM
    Pharmacol Biochem Behav; 1992 Jan; 41(1):75-8. PubMed ID: 1371611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance-P antagonists: effect on spontaneous and drug-induced locomotor activity in the rat.
    Elliott PJ; Iversen SD
    Neuropharmacology; 1987 May; 26(5):419-22. PubMed ID: 2439936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substance P, hexapeptide pGlu6(SP6-11), analgesia and serotonin depletion.
    Mészáros J; Tarchalska B; Gajewska S; Janicki P; Duriasz H; Szreniawski Z
    Pharmacol Biochem Behav; 1981 Jan; 14(1):11-5. PubMed ID: 6162166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of two C-terminal peptides of substance P on human neutrophils.
    Iwamoto I; Yamazaki H; Nakagawa N; Kimura A; Tomioka H; Yoshida S
    Neuropeptides; 1990 Jun; 16(2):103-7. PubMed ID: 1701227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats.
    Duarte FS; Testolin R; De Lima TC
    Behav Brain Res; 2004 Oct; 154(2):501-10. PubMed ID: 15313039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conditioned place preference in the corral: a procedure for measuring reinforcing properties of drugs.
    Hasenöhrl RU; Oitzl MS; Huston JP
    J Neurosci Methods; 1989 Nov; 30(2):141-6. PubMed ID: 2479799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopaminergic substrates of amphetamine-induced place preference conditioning.
    Spyraki C; Fibiger HC; Phillips AG
    Brain Res; 1982 Dec; 253(1-2):185-93. PubMed ID: 6817850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine.
    Pani L; Kuzmin A; Martellotta MC; Gessa GL; Fratta W
    Brain Res Bull; 1991 Mar; 26(3):445-7. PubMed ID: 1828708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of substance P and neurokinin A (substance K) on motor behavior: unique effect of substance P attributable to its amino-terminal sequence.
    Hall ME; Grantham P; Limoli J; Stewart JM
    Brain Res; 1987 Sep; 420(1):82-94. PubMed ID: 2445433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing the time needed to conduct conditioned place preference testing.
    Calcagnetti DJ; Schechter MD
    Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):969-76. PubMed ID: 1513934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cocaine-induced place preference conditioning: lack of effects of neuroleptics and 6-hydroxydopamine lesions.
    Spyraki C; Fibiger HC; Phillips AG
    Brain Res; 1982 Dec; 253(1-2):195-203. PubMed ID: 6817851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.